Claims

1. Use of a therapeutically effective amount of a BTK inhibitor in the manufacture of a medicament for the treatment of pemphigus vulgaris or pemphigus foliaceus in a mammal in need thereof,

wherein said BTK inhibitor is (R,E)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile.

2. The use according to claim 1, wherein said mammal is a human.

3. The use according to claim 1, wherein said mammal is an animal.

4. The use according to claim 1, wherein said mammal is a canine.

5. The use according to claim 1, wherein said BTK inhibitor is to be used in place of a corticosteriod therapy.

6. The use according to claim 1, wherein said BTK inhibitor is to be used in combination with a corticosteriod therapy.

7. The use according to claim 1, wherein said BTK inhibitor is to be administered in combination with a noncorticosteroidal immunosuppressive and/or anti-inflammatory agent.

8. The use according to claim 7, wherein said noncorticosteroidal immunosuppressive and/or anti-inflammatory agent is chosen from anti-CD20 antibody, anti-TNF antibody, anti-IL6 agent, anti-IL17 agent, and abatacept.

9. The use according to claim 7, wherein said noncorticosteroidal immunosuppressive and/or anti-inflammatory agent is chosen from rituximab, tositumomab, veltuzumab, obinutuzumab, Enbrel, and ofatumumab, or a biosimilar version thereof.

10. Use of a therapeutically effective amount of a BTK inhibitor in the manufacture of a medicament for eliminating or reducing a therapeutic dose of corticosteroid to be used in the treatment of pemphigus vulgaris or pemphigus foliaceus in a mammal in need thereof,

wherein said BTK inhibitor is (R,E)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile.

11. The use according to claim 10, wherein said mammal is a human.

12. The use according to claim 10, wherein said mammal is an animal.

13. The use according to claim 10, wherien said mammal is a canine.

14. The use according to claim 10, wherein said BTK inhibitor is to be used in place of a corticosteriod therapy.

15. The use according to claim 10, wherein said BTK inhibitor is to be used in combination with a corticosteriod therapy.

16. The use according to claim 10, wherein said BTK inhibitor is to be administered in combination with a noncorticosteroidal immunosuppressive and/or anti-inflammatory agent.

17. The use according to claim 16, wherein said noncorticosteroidal immunosuppressive and/or anti-inflammatory agent is chosen from anti-CD20 antibody, anti-TNF antibody, anti-IL6 agent, anti-IL17 agent, and abatacept.

18. The use according to claim 16, wherein said noncorticosteroidal immunosuppressive and/or anti-inflammatory agent is chosen from rituximab, tositumomab, veltuzumab, obinutuzumab, Enbrel, and ofatumumab, or a biosimilar version thereof.

19. Use of a therapeutically effective amount of a BTK inhibitor in the manufacture of a medicament for the treatment of acute flares of pemphigus vulgaris or pemphigus foliaceus in a mammal in need thereof,

wherein said BTK inhibitor is (R,E)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile.

20. The use according to claim 19, wherein said mammal is a human.

21. The use according to claim 19, wherein said mammal is an animal.

22. The use according to claim 19, wherein said mammal is a canine.

23. The use according to claim 19, wherein said BTK inhibitor is to be used in place of a corticosteriod therapy.

24. The use according to claim 19, wherein said BTK inhibitor is to be used in combination with a corticosteriod therapy.

25. The use according to claim 19, wherein said BTK inhibitor is to be administered in combination with a noncorticosteroidal immunosuppressive and/or anti-inflammatory agent.

26. The use according to claim 25, wherein said noncorticosteroidal immunosuppressive and/or anti-inflammatory agent is chosen from anti-CD20 antibody, anti-TNF antibody, anti-IL6 agent, anti-IL17 agent, and abatacept.

27. The use according to claim 25, wherein said noncorticosteroidal immunosuppressive and/or anti-inflammatory agent is chosen from rituximab, tositumomab, veltuzumab, obinutuzumab, Enbrel, and ofatumumab, or a biosimilar version thereof.